Aurobindo, Shilpa Medicare shares gain on USFDA approvals

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Aurobindo Pharma gained 1.4 percent and Shilpa Medicare rallied 3.4 percent intraday Tuesday after getting approval from the US health regulator for HIV and chemotherapy drugs, respectively.

Hyderabad-based healthcare company Aurobindo Pharma today has received tentative aporoval from the US Food and Drug Administration (USFDA) for Abacavir/Lamivudine.

Abacavir/Lamivudine is a combination drug used for the treatment of HIV infection.

The USFDA also approved chemotherapy drug Azacitidine - injection ANDA manufactured by Shilpa Medicare in its SEZ formulations facility in Jadcherla, Hyderabad.

Alembic Pharma too has received tentative approval from the US health regulator for Tadalafil that is used to treat erectile dysfunction.

At 11:50 hours IST, the scrip of Aurobindo Pharma was quoting at Rs 876, up 0.75 percent and Shilpa Medicare was up 2.54 percent at Rs 616.10 whereas Alembic Pharmaceuticals was trading at Rs 660, down 1.33 percent on the BSE.Posted by Sunil Shankar Matkar